We are live on
!
Find out more
First Manhattan Portfolio holdings
AUM
$36.1B
1-Year Est. Return
11.5%
This Fund
S&P 500
This Quarter
Est. Return
+9.64%
1 Year Est. Return
+11.5%
3 Year Est. Return
+74.65%
5 Year Est. Return
+103.66%
10 Year Est. Return
+354.63%
AUM
$27.3B
AUM Growth
+$1.22B
(+4.7%)
Cap. Flow
-$932M
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
60.57%
Holding
1,588
New
70
Increased
176
Reduced
495
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$128M |
| 2 |
ATVI
Activision Blizzard
ATVI
|
+$67.4M |
| 3 |
XIFR
XPLR Infrastructure LP
XIFR
|
+$63.8M |
| 4 |
UnitedHealth
UNH
|
+$57.4M |
| 5 |
Danaher
DHR
|
+$24.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$760M |
| 2 |
Amazon
AMZN
|
+$68.5M |
| 3 |
AbbVie
ABBV
|
+$54.2M |
| 4 |
PPLI
People Inc
PPLI
|
+$36.8M |
| 5 |
PNC Financial Services
PNC
|
+$29.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 44.09% |
| 2 | Technology | 18.28% |
| 3 | Healthcare | 10.34% |
| 4 | Consumer Discretionary | 7.89% |
| 5 | Communication Services | 5.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Service Corp International
SCI
$10.9B
| $65.8M | 0.24% |
1,018,409
+116,977
| +13% | +$7.81M |
|
52
Pinduoduo
PDD
$119B
| $63M | 0.23% |
911,290
+100,196
| +12% | +$6.88M |
|
53
Capital One
COF
$123B
| $60.8M | 0.22% |
556,265
+15,967
| +3% | +$1.6M |
|
54
Enbridge
ENB
$123B
| $52.6M | 0.19% |
1,416,864
-14,067
| -1% | -$536K |
|
55
Brookfield Asset Management
BAM
$73B
| $50.4M | 0.18% |
1,555,467
-416,446
| -21% | -$13.4M |
|
56
Cencora
COR
$59.4B
| $49.5M | 0.18% |
257,160
-599
| -0.2% | -$104K |
|
57
Stryker
SYK
$122B
| $49M | 0.18% |
160,679
-28,500
| -15% | -$8.23M |
|
58
Canadian Natural Resources
CNQ
$98B
| $48.4M | 0.18% |
1,721,518
-52,782
| -3% | -$1.51M |
|
59
Moody's
MCO
$82.5B
| $48.2M | 0.18% |
138,602
-2,894
| -2% | -$917K |
|
60
IQVIA
IQV
$34.6B
| $43.3M | 0.16% |
192,561
+2,280
| +1% | +$458K |
|
|
HOLX
61
DELISTED
Hologic
HOLX
| $41.8M | 0.15% |
516,700
| – | – |
|
62
Meta Platforms (Facebook)
META
$1.54T
| $40.2M | 0.15% |
140,071
-33,170
| -19% | -$8.19M |
|
63
Procter & Gamble
PG
$342B
| $39.5M | 0.14% |
262,858
-9,040
| -3% | -$1.36M |
|
64
Arrowhead Research
ARWR
$12.2B
| $39.2M | 0.14% |
1,099,154
+73,500
| +7% | +$2.53M |
|
65
Ingredion
INGR
$6.32B
| $37.9M | 0.14% |
357,909
-2,936
| -0.8% | -$312K |
|
66
Pfizer
PFE
$143B
| $37.9M | 0.14% |
1,032,055
-43,883
| -4% | -$1.71M |
|
67
JPMorgan Chase
JPM
$930B
| $36.9M | 0.14% |
254,690
-19,792
| -7% | -$2.72M |
|
68
Immunocore
IMCR
$1.81B
| $36.8M | 0.13% |
613,749
| – | – |
|
69
Walt Disney
DIS
$161B
| $36M | 0.13% |
403,497
-64,233
| -14% | -$6.08M |
|
70
Charter Communications
CHTR
$15.6B
| $35.9M | 0.13% |
97,841
+6,581
| +7% | +$2.25M |
|
71
Snap-on
SNA
$20.5B
| $32.7M | 0.12% |
113,324
-3,874
| -3% | -$1M |
|
72
Boston Scientific
BSX
$64.8B
| $32.5M | 0.12% |
600,442
+225
| +0% | +$11.8K |
|
|
IMGN
73
DELISTED
Immunogen Inc
IMGN
| $32.2M | 0.12% |
1,707,500
+1,700,000
| +22,667% | +$20.1M |
|
74
Starbucks
SBUX
$118B
| $31.6M | 0.12% |
328,940
-25,099
| -7% | -$2.61M |
|
75
Match Group
MTCH
$8.72B
| $31.3M | 0.11% |
748,769
-86,268
| -10% | -$3.15M |
|
Similar funds
SAM
First Manhattan's Q2 2023 Portfolio in Review
As of Q2 2023, First Manhattan held 1,588 positions worth $27.3B, up 4.7% from $26.1B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
First Manhattan withdrew a net $932M in Q2 2023, closing 161 positions and reducing 495 holdings. Its most notable exit was Enanta Pharmaceuticals, an estimated $10.7M position sold in full.
By sector, the portfolio is most concentrated in Financials at 44% of assets, down from 45% a quarter earlier, followed by Technology and Healthcare.
Against the trend, First Manhattan opened a new position in Mersana Therapeutics worth $1.87M.
- First Manhattan's largest Q2 2023 buy was Mersana Therapeutics: 22,784 shares worth $1.87M.
- First Manhattan added most to Thermo Fisher Scientific in Q2 2023, an estimated $128M increase.
- First Manhattan's biggest Q2 2023 reduction was Berkshire Hathaway Class A, cutting an estimated $760M.
- First Manhattan fully exited Enanta Pharmaceuticals in Q2 2023, selling an estimated $10.7M.
- First Manhattan's ten largest holdings make up 61% of its $27.3B portfolio in Q2 2023.
- First Manhattan opened 70 new positions and closed 161 in Q2 2023.
- First Manhattan's portfolio value rose 4.7% quarter-over-quarter to $27.3B.
Based on First Manhattan's 13F filing for Q2 2023, filed 14 Aug 2023.